BUCHANG PHARMA(SH:603858) Sou Hu Cai Jing·2025-09-19 10:11Group 1 - The core point of the news is that Buchang Pharmaceutical is expanding its business by investing in new companies through its subsidiaries, reflecting confidence in its growth prospects due to strong financial performance in the first half of 2025 [1][3][4] Group 2 - Buchang Pharmaceutical's subsidiary, Shanghai Hupu Medical Technology Co., Ltd., plans to invest a total of 4.9 million yuan to establish two new companies in partnership with Jinan Hengde Technology Development Co., Ltd. and Shanghai Guoding Technology Co., Ltd. [1] - The registered capital for Shandong Hupu Ruicheng Medical Technology Co., Ltd. is 4 million yuan, with Shanghai Hupu contributing 2.8 million yuan for a 70% stake, while Jinan Hengde contributes 1.2 million yuan for a 30% stake [3] - The registered capital for Hubei Hupu Medical Technology Co., Ltd. is 3 million yuan, with Shanghai Hupu contributing 2.1 million yuan for a 70% stake, and Shanghai Guoding contributing 900,000 yuan for a 30% stake [3] - Previously, another subsidiary, Shandong Buchang Chuanfang Pharmaceutical Co., Ltd., partnered with Zero Medical Technology (Shaanxi) Co., Ltd. to establish Shaanxi Buchang Medical Technology Co., Ltd. with a registered capital of 5 million yuan [3] Group 3 - In the first half of 2025, Buchang Pharmaceutical achieved revenue of 5.664 billion yuan and a net profit attributable to shareholders of 628 million yuan, representing year-on-year growth of 4.27% and 171.24%, respectively [4] - For the first and second quarters of 2025, the company reported revenues of 2.785 billion yuan and 2.879 billion yuan, with year-on-year growth of 5.47% and 3.14%, and net profits of 307 million yuan and 320 million yuan, reflecting year-on-year growth of 169.49% and 172.94% [4] - The significant increase in net profit is attributed to higher sales volume, lower production costs, and the reduction of amortization related to acquisitions made in previous years [4]